J&J Weighs Topamax Controlled-Release After Dropping Obesity Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
J&J weighs Topamax controlled-release formulation after dropping obesity program. Phase II study in diabetes-related obesity shows no advantage for long-acting version, J&J says. Topiramate CR was designed to avoid dosing and tolerability issues seen in obesity trials with immediate-release